An Open-label, Phase 2 Study to Assess the Safety and Efficacy of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata

EQ101-104-01

The purpose of this study is to assess the safety, PK, and PD of EQ101 as well as measure the efficacy of EQ101 at Week 24 compared to Baseline in adult subjects with moderate to severe AA. The study consists of 3 phases: a screening phase of up to 5 weeks, a treatment phase of 24 weeks, and a follow-up phase of 4 weeks. Study drug will be administered via intravenous (IV) push weekly.

2022-12-19

2024-03-01

2024-04-01

Active (not recruiting)

Early phase I

30

Key Inclusion Criteria: 1.Subjects have AA, meeting all of the following criteria: 1. Clinical diagnosis of AA with no other aetiology of hair loss ; 2. At least 35% scalp hair loss, as defined by a SALT score ≥ 35, at Screening and Baseline. Approximately 25% of subjects with 35% to \<50% scalp hair loss and 25% may have AT/AU. 3. Current episode of hair loss lasting \> 6 months to \< 7 yrs at time of Screening; and 4. No appreciable change in terminal hair regrowth within 6 months of the baseline visit. Key Exclusion Criteria: 1. Known history of, or currently experiencing, male pattern androgenetic alopecia or female pattern hair loss 2. History of scalp hair transplantation. 3. Other scalp disease that may impact AA assessment or require topical treatment 4. Unwilling to maintain a consistent hair style, including shampoo and hair products, and to refrain from weaves or extensions throughout the course of the study, or shaving of scalp. 5. Use of adhesive or difficult to remove hairpiece or wigs during the study 6. Have undergone significant trauma or major surgery within 8 weeks of the first dose of study drug or considered in imminent need for surgery or with elective surgery scheduled to occur during the study. 7. Participation in other clinical studies involving investigational drug(s) within 4 weeks prior to the baseline visit. 8. Treatment with an oral JAK inhibitor within 6 months prior to the baseline visit. 9. Have previously been treated with an oral JAK inhibitor for AA for at least 12 weeks without achieving at least a 25% improvement in SALT score. 10. Have been treated with any cell-depleting agents including but not limited to rituximab: within 6 months of the baseline visit, or 5 half-lives (if known), or until lymphocyte count returns to normal, whichever is longer. 11. Have been treated with any biologics within 12 weeks or 5 half-lives of the baseline visit, whichever is longer. 12. Have been treated with any oral immune suppressants within 8 weeks of the baseline visit. 13. Have received intralesional injections of corticosteroid or platelet-rich plasma (PRP) in the scalp within 6 weeks of the baseline visit. 14. Have used phototherapy, contact sensitisers, contact irritants, or cryotherapy within 4 weeks of the baseline visit. 15. Have used topical treatments applied to the scalp, eyebrows, or eyelashes (e.g., corticosteroid cream; JAK inhibitors; medicated shampoo; minoxidil (Rogaine); or herbal hair care that could affect AA) within 4 weeks of the baseline visit. 16. Have current or recent history of clinically significant severe, progressive, or uncontrolled renal, hepatic, haematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiovascular, psychiatric, immunologic/rheumatologic or neurologic disease; or have any other severe acute or chronic medical or psychiatric condition or laboratory abnormality 17. Have a known immunodeficiency disorder. 18. History of solid organ or haematological transplantation. 19. History of a lymphoproliferative disease or malignancy, other than adequately treated non-melanoma skin cancer or cervical carcinoma with no evidence of recurrence. 20. Have active acute or chronic infection 21. Abnormalities in clinical laboratory tests at Screening: 1. Absolute neutrophil count (ANC) \<1.0 × 109/L. 2. Liver function tests ( ALT and AST) \>3 x ULN. 3. Total bilirubin \>1.5 times ULN (unless isolated Gilbert's syndrome) 4. Serum creatinine \>1.5 ULN.

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 30, 'type': 'ESTIMATED'}}

2023-12-22